Welcome to our dedicated page for ANTERIS TECHNOLOGIES GLOBAL news (Ticker: AVR), a resource for investors and traders seeking the latest updates and insights on ANTERIS TECHNOLOGIES GLOBAL stock.
Anteris Technologies Global Corp. develops structural heart medical devices for aortic valve disease, with its lead product, the DurAVR® Transcatheter Heart Valve, designed for patients with aortic stenosis. News about AVR commonly centers on the DurAVR THV System, the ADAPT® anti-calcification tissue technology, the ComASUR® Delivery System and the company’s work in transcatheter aortic valve replacement.
Company updates also cover the PARADIGM global pivotal trial, including clinical enrollment, U.S. reimbursement under Medicare coverage for TAVR procedures, regulatory and clinical strategy, manufacturing expansion, capital raises, strategic investment activity, financial results and healthcare investor conference presentations. The company is listed on Nasdaq and ASX under the symbol AVR.
Anteris Technologies Global Corp. (AVR) has announced the pricing of its U.S. Initial Public Offering of 14,800,000 shares at $6.00 per share. Trading is expected to begin on the Nasdaq Global Market on December 13, 2024, under the ticker symbol 'AVR', with the offering closing on December 16, 2024.
The underwriters have a 30-day option to purchase up to an additional 2,220,000 shares. The company plans to use the proceeds for the development of its DurAVR® transcatheter heart valve, preparation for a global pivotal study, working capital, and debt repayment. TD Cowen, Barclays, and Cantor are joint book-running managers, with Lake Street Capital Markets as lead manager.